Cogent Biosciences, Inc.
COGT
株式のランク
#3254
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
株価
$31.37
時価総額
$5.44B
変化（1日）
4.54%
変化（1年）
93.42%
国
US
取引 Cogent Biosciences, Inc. (COGT)
カテゴリー
Healthcare
Cogent Biosciences, Inc.（COGT）の発行済株式数
June 2026 時点の発行済株式数 171.01M
Cogent Biosciences, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 171.01M です。December 2023 の終わりには、同社は 79.66M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Cogent Biosciences, Inc.（COGT）の発行済株式数の履歴（2015 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 171.01M | 64.66% |
| 2024 | 103.86M | 30.38% |
| 2023 | 79.66M | 35.61% |
| 2022 | 58.74M | 51.66% |
| 2021 | 38.73M | 249.52% |
| 2020 | 11.08M | 45.42% |
| 2019 | 7.62M | 22.43% |
| 2018 | 6.22M | -15.85% |
| 2017 | 7.40M | 26.32% |
| 2016 | 5.86M | 0.00% |
| 2015 | 5.86M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 48.47% |
US
|
|
| 396.00M | 131.57% |
US
|
|
| 478.91M | 180.06% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -63.64% |
NL
|
